Craig T Morita

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1675488/publications.pdf

Version: 2024-02-01

70	8,945	66343	102487
papers	citations	42 h-index	66 g-index

71	71	71	5890
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Recognition of a lipid antigen by CD1-restricted Î±Î²+ T cells. Nature, 1994, 372, 691-694.	27.8	962
2	Natural and synthetic non-peptide antigens recognized by human Î³Î´ T cells. Nature, 1995, 375, 155-158.	27.8	959
3	CDlb restricts the response of human CD4â^'8â^'T lymphocytes to a microbial antigen. Nature, 1992, 360, 593-597.	27.8	574
4	Evidence for extrathymic changes in the T cell receptor gamma/delta repertoire.. Journal of Experimental Medicine, 1990, 171, 1597-1612.	8.5	500
5	Direct presentation of nonpeptide prenyl pyrophosphate antigens to human Î³Î´ T cells. Immunity, 1995, 3, 495-507.	14.3	453
6	MICA Engagement by Human VÎ³2VÎ´2 T Cells Enhances Their Antigen-Dependent Effector Function. Immunity, 2001, 15, 83-93.	14.3	398
7	Nonpeptide antigens, presentation mechanisms, and immunological memory of human VÎ³2VÎ´2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens. Immunological Reviews, 2007, 215, 59-76.	6.0	386
8	Nonpeptide ligands for human gamma delta T cells.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 8175-8179.	7.1	369
9	Adaptive Immune Response of Vgamma 2Vdelta 2+ T Cells During Mycobacterial Infections. Science, 2002, 295, 2255-2258.	12.6	355
10	Human Î³Î´ T Cells Recognize Alkylamines Derived from Microbes, Edible Plants, and Tea. Immunity, 1999, 11, 57-65.	14.3	347
11	Self-Recognition of Cd1 by Î³/Î´ T Cells. Journal of Experimental Medicine, 2000, 191, 937-948.	8.5	345
12	The Syk family of protein tyrosine kinases in T-cell activation and development. Immunological Reviews, 1998, 165, 167-180.	6.0	242
13	CD1-mediated Î³/Î´ T Cell Maturation of Dendritic Cells. Journal of Experimental Medicine, 2002, 196, 1575-1584.	8.5	194
14	Cytokine Requirements for the Differentiation and Expansion of IL-17Aâ€“ and IL-22â€“Producing Human VÎ³2VÎ´2 T Cells. Journal of Immunology, 2010, 184, 7268-7280.	0.8	169
15	Flexible migration program regulates Î³Î´ T-cell involvement in humoral immunity. Blood, 2003, 102, 3693-3701.	1.4	158
16	Antigen recognition by human Î³Î´ T cells: pattern recognition by the adaptive immune system. Seminars in Immunopathology, 2000, 22, 191-217.	4.0	153
17	Butyrophilin 3A1 Plays an Essential Role in Prenyl Pyrophosphate Stimulation of Human VÎ³2VÎ´2 T Cells. Journal of Immunology, 2013, 191, 1029-1042.	0.8	142
18	Quantitative Structureâ^'Activity Relationships for Î³Î´ T Cell Activation by Bisphosphonates. Journal of Medicinal Chemistry, 2004, 47, 375-384.	6.4	114

#	Article	IF	Citations
19	VÎ³2VÎ´2 T Cell Receptor Recognition of Prenyl Pyrophosphates Is Dependent on All CDRs. Journal of Immunology, 2010, 184, 6209-6222.	0.8	107
20	Functionally distinct subsets of human Î³/Î´ T cells. European Journal of Immunology, 1991, 21, 2999-3007.	2.9	106
21	Evidence for clonal selection of gamma/delta T cells in response to a human pathogen.. Journal of Experimental Medicine, 1991, 174, 683-692.	8.5	92
22	Preferential recognition of a microbial metabolite by human VÂ2VÂ2 T cells. International Immunology, 2007, 19, 657-673.	4.0	91
23	T-cell recognition of non-peptide antigens. Current Opinion in Immunology, 1996, 8, 510-516.	5.5	89
24	fldAis an essential gene required in the 2-C-methyl-D-erythritol 4-phosphate pathway for isoprenoid biosynthesis. FEBS Letters, 2005, 579, 3802-3806.	2.8	79
25	Indirect Stimulation of Human VÎ³2VÎ´2 T Cells through Alterations in Isoprenoid Metabolism. Journal of Immunology, 2011, 187, 5099-5113.	0.8	79
26	Pyridinium-1-yl Bisphosphonates Are Potent Inhibitors of Farnesyl Diphosphate Synthase and Bone Resorption. Journal of Medicinal Chemistry, 2005, 48, 2957-2963.	6.4	77
27	Structural Features of Nonpeptide Prenyl Pyrophosphates That Determine Their Antigenicity for Human Î³Î´ T Cells. Journal of Immunology, 2001, 167, 36-41.	0.8	74
28	Sensor Function for Butyrophilin 3A1 in Prenyl Pyrophosphate Stimulation of Human VÎ³2VÎ´2 T Cells. Journal of Immunology, 2015, 195, 4583-4594.	0.8	74
29	Transendothelial chemotaxis of human Î±Î² and Î³Î´ T lymphocytes to chemokines. European Journal of Immunology, 1998, 28, 104-113.	2.9	69
30	Interactions of human alpha/beta and gamma/delta T lymphocyte subsets in shear flow with E-selectin and P-selectin.. Journal of Experimental Medicine, 1996, 183, 1193-1203.	8.5	66
31	Lipophilic Pyridinium Bisphosphonates: Potent Î³Î´ T Cell Stimulators. Angewandte Chemie - International Edition, 2010, 49, 1136-1138.	13.8	63
32	Recognition of nonpeptide prenyl pyrophosphate antigens by human Î³Î´ T cells. Microbes and Infection, 1999, 1, 175-186.	1.9	62
33	Phosphonosulfonates Are Potent, Selective Inhibitors of Dehydrosqualene Synthase and Staphyloxanthin Biosynthesis in Staphylococcus aureus. Journal of Medicinal Chemistry, 2009, 52, 976-988.	6.4	59
34	Regulation and function of IL-17A- and IL-22-producing Î³Î´ T cells. Cellular and Molecular Life Sciences, 2011, 68, 2371-2390.	5.4	58
35	Zoledronic acid-induced expansion of Î³Î´ T cells from early-stage breast cancer patients: effect of IL-18 on helper NK cells. Cancer Immunology, Immunotherapy, 2013, 62, 677-687.	4.2	55
36	Conservation of Nonpeptide Antigen Recognition by Rhesus Monkey VÎ³2VÎ´2 T Cells. Journal of Immunology, 2003, 170, 3696-3706.	0.8	52

#	Article	IF	Citations
37	Isoprenoid Biosynthesis as a Drug Target:Â Bisphosphonate Inhibition ofEscherichia coliK12 Growth and Synergistic Effects of Fosmidomycin. Journal of Medicinal Chemistry, 2006, 49, 7331-7341.	6.4	52
38	Superantigen Recognition by Î³Î´ T Cells. Immunity, 2001, 14, 331-344.	14.3	50
39	Comparison of Î³Î´ T cell responses and farnesyl diphosphate synthase inhibition in tumor cells pretreated with zoledronic acid. Cancer Science, 2013, 104, 536-542.	3.9	50
40	Photoaffinity Antigens for Human Î³Î´ T Cells. Journal of Immunology, 2008, 181, 7738-7750.	0.8	49
41	Enhancing adoptive cancer immunotherapy with VÎ³2VÎ´2 T cells through pulse zoledronate stimulation. , 2017, 5, 9.		49
42	Anti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug. Scientific Reports, 2017, 7, 5987.	3.3	49
43	Direct presentation of non-peptide prenyl pyrophosphate antigens to human Î³Î´ T cells. Research in Immunology, 1996, 147, 347-353.	0.9	48
44	Calmodulin kinase II regulates the maturation and antigen presentation of human dendritic cells. Journal of Leukocyte Biology, 2005, 78, 1397-1407.	3.3	43
45	Expansion of human Î³Î´ T cells for adoptive immunotherapy using a bisphosphonate prodrug. Cancer Science, 2018, 109, 587-599.	3.9	40
46	Chemo-Immunotherapeutic Antimalarials Targeting Isoprenoid Biosynthesis. ACS Medicinal Chemistry Letters, 2013, 4, 423-427.	2.8	35
47	Targeting Cancer Cells with a Bisphosphonate Prodrug. ChemMedChem, 2016, 11, 2656-2663.	3.2	35
48	Recognition of nonpeptide antigens by T cells. Journal of Molecular Medicine, 1996, 74, 223-231.	3.9	31
49	Synthesis of Pyrophosphate-Containing Compounds that Stimulate VγVδ2 T Cells: Application to Cancer Immunotherapy. Medicinal Chemistry, 2007, 3, 85-99.	1.5	28
50	Structural Studies of VÎ³2VÎ´2 T Cell Phosphoantigens. Chemistry and Biology, 2006, 13, 985-992.	6.0	23
51	Metabolic Engineering of Salmonella Vaccine Bacteria To Boost Human VÎ³2VÎ´2 T Cell Immunity. Journal of Immunology, 2014, 193, 708-721.	0.8	22
52	Synthesis of chiral phosphoantigens and their activity in Î³Î´ T cell stimulation. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 4471-4477.	2.2	20
53	Identification of an Important Immunological Difference between Virulent Varicella-Zoster Virus and Its Avirulent Vaccine: Viral Disruption of Dendritic Cell Instruction. Journal of Immunology, 2010, 185, 488-497.	0.8	18
54	Phenotypic and functional alterations of VÎ³2VÎ´2 T cell subsets in patients with active nasopharyngeal carcinoma. Cancer Immunology, Immunotherapy, 2009, 58, 1095-1107.	4.2	16

#	Article	IF	Citations
55	Critical Roles for Coiled-Coil Dimers of Butyrophilin 3A1 in the Sensing of Prenyl Pyrophosphates by Human Vγ2Vδ2 T Cells. Journal of Immunology, 2019, 203, 607-626.	0.8	16
56	Comparison of a Novel Bisphosphonate Prodrug and Zoledronic Acid in the Induction of Cytotoxicity in Human Vγ2Vδ2 T Cells. Frontiers in Immunology, 2020, 11, 1405.	4.8	16
57	PD-1 checkpoint blockade enhances adoptive immunotherapy by human Vγ2Vδ2 T cells against human prostate cancer. OncoImmunology, 2021, 10, 1989789.	4.6	15
58	A Crystallographic Investigation of Phosphoantigen Binding to Isopentenyl Pyrophosphate/Dimethylallyl Pyrophosphate Isomerase. Journal of the American Chemical Society, 2005, 127, 536-537.	13.7	12
59	Recognition of mycobacterial antigens by γδ T cells. Research in Immunology, 1990, 141, 645-651.	0.9	11
60	Live Cell Labeling with Terpyridine Derivative Proligands to Measure Cytotoxicity Mediated by Immune Cells. ChemMedChem, 2017, 12, 2006-2013.	3.2	9
61	Identification of guinea pig γδ T cells and characterization during pulmonary tuberculosis. Veterinary Immunology and Immunopathology, 2004, 102, 33-44.	1.2	7
62	Synthesis and Immunomodulatory Activity of Fluorineâ€Containing Bisphosphonates. ChemMedChem, 2019, 14, 462-468.	3.2	7
63	T cell receptor-dependent activation of human lymphocytes through cell surface ganglioside GT1b: implications for innate immunity. European Journal of Immunology, 2000, 30, 3199-3206.	2.9	6
64	ANTIRETINOBLASTOMA MONOCLONAL ANTIBODIES. Retina, 1983, 3, 200-205.	1.7	5
65	Determination of human γδ T cellâ€“mediated cytotoxicity using a non-radioactive assay system. Journal of Immunological Methods, 2019, 466, 32-40.	1.4	4
66	Necroptosis of Dendritic Cells Promotes Activation of γδ T Cells. Journal of Innate Immunity, 2016, 8, 479-492.	3.8	3
67	Chemokine biology of NK cells and γδ T cells. , 2006, , 59-78.		2
68	Synthesis and immunological evaluation of the 4-β-glucoside of HMBPP. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 811-813.	2.2	1
69	Anti-PD-1 and Anti-PD-L1 mAbs. , 2016, , 283-294.		1
70	Abstract 3628: PD-1 checkpoint blockade therapy enhances adoptive immunotherapy by human Vγ2Vδ2 T cells against prostate tumors in a preclinical model. , 2018, , .		0